

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2329131/publications.pdf>

Version: 2024-02-01

9
papers

86
citations

1937457

4
h-index

2053595

5
g-index

10
all docs

10
docs citations

10
times ranked

103
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting and Therapeutic Monitoring of H3K27M-Mutant Glioma. <i>Current Oncology Reports</i> , 2020, 22, 19.	1.8	35
2	Electronic DNA Analysis of CSF Cell-free Tumor DNA to Quantify Multi-gene Molecular Response in Pediatric High-grade Glioma. <i>Clinical Cancer Research</i> , 2020, 26, 6266-6276.	3.2	26
3	Panobinostat penetrates the blood-brain barrier and achieves effective brain concentrations in a murine model. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 555-562.	1.1	15
4	Comparative pharmacokinetic analysis of the blood-brain barrier penetration of dasatinib and ponatinib in mice. <i>Leukemia and Lymphoma</i> , 2021, 62, 1990-1994.	0.6	9
5	Targeted agents recommended by the CNS TAP tool compared to those selected by a tumor board in a molecularly-driven clinical trial in children and young adults with DIPG.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2048-2048.	0.8	0
6	EPCT-02. COMPARISON OF TARGETED AGENTS RECOMMENDED BY THE CNS-TAP TOOL TO THOSE SELECTED BY A TUMOR BOARD IN A MOLECULARLY-DRIVEN DIPG CLINICAL TRIAL. <i>Neuro-Oncology</i> , 2021, 23, i46-i46.	0.6	0
7	CLRM-06. COMPARISON OF INDIVIDUALIZED ANTI-CANCER THERAPY REGIMENS RECOMMENDED BY A MULTIDISCIPLINARY MOLECULARLY-DRIVEN TUMOR BOARD IN A PEDIATRIC DIPG CLINICAL TRIAL (PNOC003) VERSUS THOSE SELECTED BY THE CNS-TAP TOOL. <i>Neuro-Oncology Advances</i> , 2021, 3, iv2-iv2.	0.4	0
8	DIPG-08. ELECTRONIC SEQUENCING PROVIDES OPTIMIZED QUANTIFICATION OF SERIAL, MULTI-GENE MOLECULAR RESPONSE IN THE CSF OF CHILDREN WITH HIGH-GRADE GLIOMA. <i>Neuro-Oncology</i> , 2020, 22, iii288-iii288.	0.6	0
9	INNV-16. CNS-TAP TOOL RECOMMENDATIONS OF TARGETED ANTI-CANCER AGENTS COMPARED TO THOSE SELECTED BY A MULTIDISCIPLINARY TUMOR BOARD IN A MOLECULARLY-DRIVEN DIPG CLINICAL TRIAL (PNOC003). <i>Neuro-Oncology</i> , 2021, 23, vi108-vi108.	0.6	0